BALTIMORE, June 22, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of Ohr Pharmaceutical, Inc. (OTCBB:OHRP), a pharmaceutical firm engaged in the development of drugs with large underserved markets.
Ohr has 2 drugs in Phase II development, including a treatment for cancer cachexia and Wet-AMD (Age-related macular degeneration.) The combined markets for these treatments are $4 billion.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"We view Ohr as a stock that offers a rare opportunity to get in on the ground floor of a mature, late stage biotech. Two of its Phase II development drugs currently have no approved therapy and have demonstrated stellar efficacy and safety profile results. Plus, Ohr is expected to achieve a series of milestones this year culminating in the release of Phase IIb results for its cancer cachexia drug in late 4Q10. Ohr presents great value and home run potential with its products under development."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit www.goldmanresearch.com.
About Ohr Pharmaceutical, Inc.: Ohr Pharmaceutical, Inc. (OTCBB:OHRP) is focused on the development of two drugs: OHR/AVR 118 for the treatment of Cancer Cachexia and EVIZON(TM) for the treatment of the wet form of age-related macular degeneration (Wet-AMD). Cancer Cachexia, the syndrome of body wasting that affects late-stage cancer patients, is a debilitating condition which adversely affects their quality of life. Wet-AMD is a leading cause of vision loss and blindness in the elderly population. The promise shown by Ohr Pharmaceutical's products pipeline offer a new ray of hope to patients suffering from these devastating diseases.
For more information, visit www.ohrpharmaceutical.com